Literature DB >> 21435929

Trends in the quality of care for elderly people with type 2 diabetes: the need for improvements in safety and quality (the 2001 and 2007 ENTRED Surveys).

Carole Pornet1, Isabelle Bourdel-Marchasson, Pierre Lecomte, Eveline Eschwège, Isabelle Romon, Sandrine Fosse, Frank Assogba, Candice Roudier, Anne Fagot-Campagna.   

Abstract

AIM: This study aimed to characterize the sociodemographic data, health status, quality of care and 6-year trends in elderly people with type 2 diabetes.
METHODS: This study used two French cross-sectional representative surveys of adults of all ages with all types of diabetes (Entred 2001 and 2007), which combined medical claims, and patient and medical provider questionnaires. The 2007 data in patients with type 2 diabetes aged 65 years or over (n=1766) were described and compared with the 2001 data (n=1801).
RESULTS: Since 2001, obesity has increased (35% in 2007; +7 points since 2001) while written nutritional advice was less often provided (59%; -6 points). Mean HbA(1c) (7.1%; -0.2%), blood pressure (135/76 mmHg; -4/-3 mmHg) and LDL cholesterol (1.04 g/L; -0.21 g/L) declined, while the use of medication increased: at least two OHAs, 34% (+4 points); OHA(s) and insulin combined, 10% (+4 points); antihypertensive treatment, 83% (+4 points); and statins 48% (+26 points). Severe hypoglycaemia remained frequent (10% had an event at least once a year). The overall prevalence of complications increased. Renal complications were not monitored carefully enough (missing value for albuminuria: 42%; -4.5 points), and 46% of those with a glomerular filtration rate less than 60 mL/min/1.73 m² were taking metformin.
CONCLUSION: Elderly people with type 2 diabetes are receiving better quality of care and have better control of cardiovascular risk factors than before. However, improvement is still required, in particular by performing better screening for complications. In this patient population, it is important to carefully monitor the risks for hypoglycaemia, hypotension, malnutrition and contraindications related to renal function.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21435929     DOI: 10.1016/j.diabet.2011.02.001

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  14 in total

1.  A prospective observational study of quality of diabetes care in a shared care setting: trends and age differences (ZODIAC-19).

Authors:  Kornelis J J van Hateren; Iefke Drion; Nanne Kleefstra; Klaas H Groenier; Sebastiaan T Houweling; Klaas van der Meer; Henk J G Bilo
Journal:  BMJ Open       Date:  2012-08-29       Impact factor: 2.692

2.  Medication adherence in type 2 diabetes: the ENTRED study 2007, a French Population-Based Study.

Authors:  Michel Tiv; Jean-François Viel; Frédéric Mauny; Eveline Eschwège; Alain Weill; Cécile Fournier; Anne Fagot-Campagna; Alfred Penfornis
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

Review 3.  Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus.

Authors:  Sylvie Dejager; Anja Schweizer; James E Foley
Journal:  Vasc Health Risk Manag       Date:  2012-05-18

4.  Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study.

Authors:  Alfred Penfornis; Béatrice Fiquet; Jean Frédéric Blicklé; Sylvie Dejager
Journal:  Diabetes Metab Syndr Obes       Date:  2015-07-03       Impact factor: 3.168

5.  Diabetes care in Switzerland: good, but perfectible: a population-based cross-sectional survey.

Authors:  Isabelle Peytremann-Bridevaux; Julie Bordet; Bernard Burnand
Journal:  BMC Health Serv Res       Date:  2013-06-25       Impact factor: 2.655

6.  Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment.

Authors:  Anja Schweizer; Sylvie Dejager
Journal:  Diabetes Ther       Date:  2013-07-03       Impact factor: 2.945

7.  Efficacy and safety of insulin lispro in geriatric patients with type 2 diabetes: a retrospective analysis of seven randomized controlled clinical trials.

Authors:  Bradley H Curtis; Tina M Rees; Kim A Gaskins; Justo Sierra-Johnson; Rong Liu; Honghua H Jiang; John H Holcombe
Journal:  Aging Clin Exp Res       Date:  2014-02       Impact factor: 3.636

8.  How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.

Authors:  Alfred Penfornis; Jean Frédéric Blicklé; Béatrice Fiquet; Stéphane Quéré; Sylvie Dejager
Journal:  Vasc Health Risk Manag       Date:  2014-06-13

9.  Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study.

Authors:  Dominique Simon; Bruno Detournay; Evelyne Eschwege; Stephane Bouée; Jacques Bringer; Claude Attali; Sylvie Dejager
Journal:  Diabetes Ther       Date:  2014-04-12       Impact factor: 2.945

10.  Age-related differences in diabetes care outcomes in Korea: a retrospective cohort study.

Authors:  Myung Ki; Sujin Baek; Young-duk Yun; Namhoon Kim; Martin Hyde; Baegju Na
Journal:  BMC Geriatr       Date:  2014-10-16       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.